185 related articles for article (PubMed ID: 10391667)
1. Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this "adaptive response" in mice.
Rakhit A; Yeon MM; Ferrante J; Fettner S; Nadeau R; Motzer R; Bukowski R; Carvajal DM; Wilkinson VL; Presky DH; Magram J; Gately MK
Clin Pharmacol Ther; 1999 Jun; 65(6):615-29. PubMed ID: 10391667
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer.
Portielje JE; Kruit WH; Schuler M; Beck J; Lamers CH; Stoter G; Huber C; de Boer-Dennert M; Rakhit A; Bolhuis RL; Aulitzky WE
Clin Cancer Res; 1999 Dec; 5(12):3983-9. PubMed ID: 10632329
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma.
Motzer RJ; Rakhit A; Schwartz LH; Olencki T; Malone TM; Sandstrom K; Nadeau R; Parmar H; Bukowski R
Clin Cancer Res; 1998 May; 4(5):1183-91. PubMed ID: 9607576
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB
Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
[TBL] [Abstract][Full Text] [Related]
5. Interferon-gamma and CXC chemokine induction by interleukin 12 in renal cell carcinoma.
Bukowski RM; Rayman P; Molto L; Tannenbaum CS; Olencki T; Peereboom D; Tubbs R; McLain D; Budd GT; Griffin T; Novick A; Hamilton TA; Finke J
Clin Cancer Res; 1999 Oct; 5(10):2780-9. PubMed ID: 10537342
[TBL] [Abstract][Full Text] [Related]
6. Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses.
Portielje JE; Lamers CH; Kruit WH; Sparreboom A; Bolhuis RL; Stoter G; Huber C; Gratama JW
Clin Cancer Res; 2003 Jan; 9(1):76-83. PubMed ID: 12538454
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of IL-18 receptor in cancer patients: its clinical significance.
Kobashi K; Iwagaki H; Yoshino T; Morimoto Y; Kohka H; Kodama M; Nishibori M; Akagi T; Tanaka N
Anticancer Res; 2001; 21(5):3285-93. PubMed ID: 11848485
[TBL] [Abstract][Full Text] [Related]
8. Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: a mechanism of immune escape.
Rayman P; Uzzo RG; Kolenko V; Bloom T; Cathcart MK; Molto L; Novick AC; Bukowski RM; Hamilton T; Finke JH
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S81-7. PubMed ID: 10685665
[TBL] [Abstract][Full Text] [Related]
9. TH1/TH2 serum cytokine profiles and soluble TNF-receptor response in patients with chronic hepatitis C during recombinant human interleukin-12 (rHuIL-12) treatment.
Teuber G; Rossol S; Lee JH; Dietrich CF; Zeuzem S
Z Gastroenterol; 2002 Jul; 40(7):487-95. PubMed ID: 12122596
[TBL] [Abstract][Full Text] [Related]
10. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C.
Zeuzem S; Hopf U; Carreno V; Diago M; Shiffman M; Grüne S; Dudley FJ; Rakhit A; Rittweger K; Yap SH; Koff RS; Thomas HC
Hepatology; 1999 Apr; 29(4):1280-7. PubMed ID: 10094976
[TBL] [Abstract][Full Text] [Related]
11. Intranasal IL-12 produces discreet pulmonary and systemic effects on allergic inflammation and airway reactivity.
Matsuse H; Kong X; Hu J; Wolf SF; Lockey RF; Mohapatra SS
Int Immunopharmacol; 2003 Apr; 3(4):457-68. PubMed ID: 12689651
[TBL] [Abstract][Full Text] [Related]
12. Autocrine regulation of IL-12 receptor expression is independent of secondary IFN-gamma secretion and not restricted to T and NK cells.
Thibodeaux DK; Hunter SE; Waldburger KE; Bliss JL; Trepicchio WL; Sypek JP; Dunussi-Joannopoulos K; Goldman SJ; Leonard JP
J Immunol; 1999 Nov; 163(10):5257-64. PubMed ID: 10553047
[TBL] [Abstract][Full Text] [Related]
13. IL-12 stimulates an antiviral type 1 cytokine response but lacks adjuvant activity in IFN-gamma-receptor-deficient mice.
Schijns VE; Haagmans BL; Horzinek MC
J Immunol; 1995 Sep; 155(5):2525-32. PubMed ID: 7650382
[TBL] [Abstract][Full Text] [Related]
14. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-12 and -18 levels in peritoneal dialysate effluent correlate with the outcome of peritonitis in patients undergoing peritoneal dialysis: implications for the Type I/Type II T-cell immune response.
Wang HH; Lin CY
Am J Kidney Dis; 2005 Aug; 46(2):328-38. PubMed ID: 16112053
[TBL] [Abstract][Full Text] [Related]
16. Interferon-gamma produced by interleukin-12-activated tumor infiltrating CD8+T cells directly induces apoptosis of mouse hepatocellular carcinoma.
Komita H; Homma S; Saotome H; Zeniya M; Ohno T; Toda G
J Hepatol; 2006 Nov; 45(5):662-72. PubMed ID: 16935390
[TBL] [Abstract][Full Text] [Related]
17. Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma.
Propper DJ; Chao D; Braybrooke JP; Bahl P; Thavasu P; Balkwill F; Turley H; Dobbs N; Gatter K; Talbot DC; Harris AL; Ganesan TS
Clin Cancer Res; 2003 Jan; 9(1):84-92. PubMed ID: 12538455
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.
Gollob JA; Veenstra KG; Parker RA; Mier JW; McDermott DF; Clancy D; Tutin L; Koon H; Atkins MB
J Clin Oncol; 2003 Jul; 21(13):2564-73. PubMed ID: 12829677
[TBL] [Abstract][Full Text] [Related]
19. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma.
Motzer RJ; Rakhit A; Thompson JA; Nemunaitis J; Murphy BA; Ellerhorst J; Schwartz LH; Berg WJ; Bukowski RM
J Interferon Cytokine Res; 2001 Apr; 21(4):257-63. PubMed ID: 11359657
[TBL] [Abstract][Full Text] [Related]
20. [TH1 response in the experimental infection with Trypanosoma cruzi].
Cardoni RL; Antúnez MI; Abrami AA
Medicina (B Aires); 1999; 59 Suppl 2():84-90. PubMed ID: 10668248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
